Home » Authors » Kelly Gable, PharmD, BCPP

Kelly Gable, PharmD, BCPP

Assistant professor of pharmacy practice, Southern Illinois University, Edwardsville, School of Pharmacy

Articles

ARTICLES

Future Developments in Antidepressant Therapy

May 1, 2012

Kelly Gable, PharmD, BCPP and Steve Balt, MD

Kelly Gable, PharmD, BCPP Assistant professor of pharmacy practice, Southern Illinois University, Edwardsville, School of Pharmacy Dr. Gable has disclosed that she has no relevant relationships or financial interests in any commercial companies pertaining to this educational activity. Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.

In 2011 in the pages of TCPR, we asked, “What’s new in antidepressant treatment?” The answer was “not much” (TCPR, April 2011). In 2012, unfortunately, the answer isn’t very different.

Long Acting Injectable Antipsychotics: A Primer

December 1, 2010

Kelly Gable, PharmD, BCPP and Daniel Carlat, MD

Kelly Gable, PharmD, BCPP Assistant professor of pharmacy practice Southern Illinois University, Edwardsville, School of Pharmacy Daniel Carlat, MD Editor-in-chief, The Carlat Psychiatry Report

They used to be called “depot” antipsychotics, but the powers that be have renamed them “long acting injectables” (LAIs), presumably to help remove some of the stigma associated with their use. But no matter what you call them, suddenly every drug company is racing to introduce its own LAI neuroleptic.

Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.